SAN DIEGO and DUBAI, United Arab Emirates, Jan. 4, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) and Elis Pharmaceuticals (“Elis”), announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio’s new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. “This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world,” said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
